Stryker Co. (NYSE:SYK) Shares Bought by Oak Associates Ltd. OH

Oak Associates Ltd. OH boosted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 43.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,164 shares of the medical technology company's stock after buying an additional 1,860 shares during the quarter. Oak Associates Ltd. OH's holdings in Stryker were worth $2,219,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Norges Bank acquired a new stake in Stryker in the 4th quarter valued at about $1,710,744,000. Raymond James Financial Inc. acquired a new stake in Stryker in the fourth quarter valued at approximately $353,394,000. FMR LLC lifted its stake in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in Stryker by 52,520.8% during the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after acquiring an additional 595,061 shares in the last quarter. Finally, APG Asset Management N.V. increased its position in shares of Stryker by 1,695.0% in the 4th quarter. APG Asset Management N.V. now owns 370,226 shares of the medical technology company's stock valued at $128,730,000 after purchasing an additional 349,601 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Argus set a $450.00 target price on shares of Stryker in a report on Monday, February 3rd. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Citigroup restated a "buy" rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Finally, Barclays increased their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $423.05.

Remove Ads

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Trading Down 1.9 %

Shares of SYK traded down $6.54 during mid-day trading on Tuesday, hitting $346.88. The company had a trading volume of 1,670,378 shares, compared to its average volume of 1,360,480. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business's 50-day simple moving average is $374.63 and its 200-day simple moving average is $373.58. The stock has a market cap of $132.40 billion, a PE ratio of 44.70, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. Stryker's payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.